Strategic Partnerships Nomic Bio has been actively forming collaborations with leading institutions such as Wellcome Sanger Institute and Broad Clinical Labs to scale its proteomics platform, indicating strong inbound interest and potential for co-development or enterprise-tier partnerships with CROs, clinical labs, and biotech firms.

Scale Proteomics The company emphasizes scalable, high-plex proteomics across large sample sets (PBMC profiling) and has published sizable datasets, suggesting opportunities to upsell turnkey proteomics services, data integration, and analytics outputs to pharma, biotech, and academic clients pursuing large cohort studies.

Data Platform Nomic’s 1.4 million datapoint PBMC cytokine perturbation dataset and accessible Nomic Portal highlight a mature data infrastructure ideal for enterprise customers seeking analysis-ready outputs, potential for premium data licenses, dashboards, and custom analytics services.

Funding Momentum With a Series B funding of 42 million and ongoing expansion efforts, there is budgetary and strategic runway to pursue multi-year contracts, platform licensing, and integration projects with larger biopharma and contract labs.

Integrated Workflows Recent integrations with Broad Clinical Labs and emphasis on end-to-end proteomics workflows signal a readiness to embed Nomic’s proteomics capabilities into established discovery and translational pipelines, presenting cross-sell opportunities to existing lab networks and drug development programs.